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INTRODUCTION
Central neurocytoma (CN) was described as a distinct clinicopathologic entity by Hassoun 
et al. in 1982.[18] CN account for <1% of all central nervous system (CNS) neoplasms.[33] It is 
suggested that CN might be an embryonal tumor originating from the multipotent germinal 
ABSTRACT
Background: e purpose of the presented work is to evaluate the last decade’s experience in surgical management 
of central neurocytoma (CN) and elucidate on the treatment strategies and new options.
Methods: e current series consists of the remaining 125  patients (70  females and 55  males) operated on 
during the past decade from 2008 to 2018. Most tumors were resected through transcortical (n = 76, 61%), or 
transcallosal (n = 40, 32%) approaches. In 5 (4%) patients with predominantly posterior location of the tumor, 
non-dominant superior parietal lobule approach was utilized. Both approaches (transcortical + transcallosal) 
were used in 4 (3%) of cases. Seven consecutive patients with large CN underwent prophylactic intraventricular 
stenting to prevent hydrocephalus.
Results: Gross total resection was achieved in 45  patients (36%), subtotal resection (STR) in 40  (32%) cases. 
After surgery, 63 (50%) patients had neurocognitive problems, including disorientation, attention deficit, global 
amnesia, short-term memory deficits, and perceptual motor and social cognition problems. A total of 26 patients 
(21%) had postoperative hemorrhage in the resection bed. Obstructive hydrocephalus was noted in 25  (20%) 
patients. e entrapment of the occipital and/or temporal horns was observed in seven cases. None of the seven 
patients with prophylactic intraventricular stents required shunting.
Conclusion: Although high rates of gross total or STR can be expected, the mortality and morbidity remain 
significant even in the modern neurosurgical era. Prophylactic intraventricular stenting in patients with large 
posteriorly located tumors with hydrocephalus may prevent ventricular entrapment and shunting. e main risk 
factors for recurrence are presence of residual disease and Ki-67 index over 5%. Recurrent symptomatic tumors 
should be treated surgically, whereas asymptomatic progression can be managed with stereotactic radiosurgery. 
Both treatment modalities are associated with low risk of complications and high tumor control rates.
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matrix cells located in the lateral ventricles.[2] CN is 
biologically benign lesions composed of small uniform cells 
with round nuclei and perinuclear halos. Mitotic figures 
are rare.[17] is tumor may be associated with a relatively 
favorable prognosis.[24-54] Patients with CN may present 
with a wide variety of symptoms, primarily related to the 
long-standing intracranial hypertension and obstructive 
hydrocephalus. Maximally aggressive surgical excision 
is a widely accepted mainstay of treatment. According to 
the literature, it can be achieved in only 50–60% of the 
patients.[24-41] Surgical challenges are the result of the deep 
location, frequently large size at presentation, and high 
vascularity.[41]
e largest clinical series included 438 patients by Rades and 
Schild 92  cases by Qian et al., 84 by Konovalov et al., and 
63 cases by Wang et al.[24,41,43,51] Early publications described 
high rate of complications and low resection rates. In the 
original series of Hassoun et al. and subsequent report by 
Nishio et al., only 50% of the patients had gross total resection 
(GTR).[19,38] In the last decade, however, a higher number 
of patients underwent more radical resections, ranging 
from 71% to 91% with acceptable morbidity.[8,23,41] In this 
manuscript, the authors systematized the results of surgical 
treatment of CN in the past decade from 2008 to 2018. e 
main focus of this largest surgical series of patients with CN 
to date is the analysis of anatomy and location of the tumor, 
proper selection of surgical approaches, and evaluation of 
outcomes.
MATERIALS AND METHODS
A total of 250  patients with CN were operated on at our 
institution from 1992 to 2018. e current series consists 
of the 125  patients (70  females and 55  males) operated on 
during the past decade from 2008 to 2018. e patients’ age 
ranged from 14 to 66 years (median 30 years). e study was 
approved by the Research and Ethics Committee. e charts, 
radiographic data, and surgical records were retrospectively 
reviewed. e following data were extracted and analyzed: 
age, sex, clinical presentation, radiographic characteristics 
of the lesions, including size, location, and relationship with 
surrounding anatomical structures, enhancement pattern, 
intraoperative findings, extent of resection, perioperative 
complications, and causes of mortality. All patients had their 
first postoperative brain magnetic resonance imaging (MRI) 
3  months after surgery, followed by annual MR studies, 
unless clinically indicated otherwise.
e extent of tumor resection (ETR) was defined as (1) 
GTR, when complete removal without any obvious residual 
was achieved, (2) subtotal resection (STR), when small 
residual nodular enhancement, or linear enhancement of the 
resection bed, indistinguishable from the residual tumor was 
present, and (3) partial resection (PR), when more than 10% 
of the tumor was seen on postoperative MRI. e estimation 
of the EOR was reported by the staff neuroradiologists based 
on the postoperative MRI 3 months after surgery. All patients 
underwent neuropsychological and psychiatric evaluation by 
the staff psychologist and psychiatrist.
Statistical analysis
To establish the effect of clinical factors on overall survival, 
a Kaplan–Meier analysis was performed. A  log-rank test 
(logarithmic rank test) and a Chi-square test were used 
to assess differences between the two groups forming 
the Kaplan–Meier curves in analysis 2 (e.g.  complete or 
incomplete resection) to identify the validity of differences 
between the analyzed groups and obtain of risk ratio (RR). 
A single-factor regression analysis, all significant factors for 
which P < 0.05 was included in the multi-factor regression 
analysis (Cox Proportional Hazards Model), was used to 
assess the prognostic role of different factors. Assessment 
of recurrence was performed by multifactorial regression 
analysis with RR and 95% confidence interval. Differences 
were considered valid at P < 0.05. Statistical analysis was 
performed using the program “MedCalc” (version 19.6).
Clinical presentation
Symptoms associated with raised intracranial pressure (ICP) 
were the most common clinical presenting findings in this series. 
Seventy-eight patients (62%) had evidence of papilledema. 
e extent of papilledema was graded according to the Frisen 
grading system.[41] Fundoscopic evaluation was performed 
preoperatively and postoperatively in each patient.[13]
Fifteen patients (12%) presented with hemiparesis. Memory 
changes were noted in 40  patients (32%). Psychiatric and 
cognitive problems were documented in 28  patients (22%). 
Clinical findings are presented in more detail in [Tables 1 and 2].
Preoperatively, 76 patients had a Glasgow coma scale (GCS) 
of 14–15, whereas 49 patients had GCS of 12–13.
Radiographic characteristics
All 125  patients underwent an MRI of the brain with 
utilization of the standard brain tumor protocol with contrast. 
In 83 patients (66%), the tumor was isointense to the brain 
cortex on T1-weighted images. On T2 images, CN was seen as 
heterogeneous lesions with multiple small hypointense cyst-
like areas, which were noted in 69% of the patients. About 
60% of the neoplasms were larger than 4  cm in maximum 
diameter. e largest mass had the longest linear dimension 
of 8.0 cm. CN showed considerable anatomical variability in 
their location within the ventricular system.
Based on the tumor size, we propose the following 
classification: Group  I: small tumors (<2  cm); Group  II: 
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Table 2: Papilledema in patients with CN according to the Frisen 
grading system.
Papilledema n
Normal Optic Disc 47 (38%)
Minimal Degree of Edema 11(9%)
Low Degree of Edema 16 (12%)
Moderate Degree of Edema 21 (16%)
Marked Degree of Edema 14 (11%)
Severe papilledema with atrophy and hemorrhages 30 (24%)
CN: Central neurocytoma
Table 1: Clinical presentation of 125 patients with CN.
Signs of increased ICP (chronic headaches, 
nausea, and vomiting)
78 (62%)
Memory decline 40 (32%)
Psychiatric and cognitive problems 28 (22%)
Hemiparesis and hyperreflexia 15 (12%)
Visual field cuts 2 (1.7%)
Double vision due to abducens nerve palsy 2 (1.7%)
Seizures 8 (6%)
ICP: Intracranial pressure, CN: Central neurocytoma
medium size (2–4  cm); Group  III: large (4–6  cm); and 
Group  IV: giant (>6  cm). According to the location, the 
tumors can be classified into Group A: anterior (located in the 
anterior horns); Group B: medial (located in the body of the 
lateral ventricle); Group C: posterior (in the trigonum and the 
occipital horn); and Group  D: extensive (involving several 
parts of the lateral ventricles or casting them) [Figure  1]. 
e numbers of patients in each group are summarized in 
[Table 3]. In 30  patients, the tumor was extending into the 
third ventricle. In Group  A patients, tumor extension onto 
the third ventricle was observed in 8 of 43 cases; in Group B 
patients, in 12 of 54; and in 10 of 17 patients in Group D.
Indications for surgery
Our approach was to recommend surgical resection in 
all symptomatic patients with radiographic findings of 
intraventricular mass suggestive of CN. Surgery was 
contraindicated in patients with significant comorbidities, in 
whom general anesthesia and potentially, prolonged surgery 
was felt to be risky. In the absence of major comorbidities 
and contraindications to general anesthesia, we recommend 
maximally safe resection of even very large and giant tumors, 
as surgery can be the patients’ only chance for survival. In 
patients harboring tumors with very significant infiltrative 
component, surgical indications are not straightforward. In 
such instances, operative treatment may be considered on a 
case by case basis with the main objectives to establish tissue 
diagnosis, achieve maximally safe debulking and palliation.
Surgical treatment
Surgical approaches
Most tumors in our series were resected through transcortical 
(n = 76, 61%), or transcallosal (n = 40, 32%) approaches. In 
five (4%) patients with predominantly posterior location of 
the tumor, non-dominant superior parietal lobule approach 
was utilized.
Anterior frontal transcortical approach is used in patients 
with (1) CN located predominantly in the anterior horn 
and the body of the lateral ventricle, (2) medial tumors with 
lateral extension, and (3) large CN with lateral extension, 
as well as tumors spreading to the contralateral side, but 
only when ventriculomegaly was present. In patients with 
very large tumors, casting most of the lumen of the lateral 
ventricle, the craniotomy window had to be shifted more 
anteriorly to achieve a favorable angle of attack along the 
main axis of the neoplasm.
Transcallosal approach was preferred exposure in (1) 
patients with medial or unilateral location of the tumor 
without significant lateral extension and (2) small to 
medium size medial tumors in both ventricles. e main 
advantages of this approach were optimal visualization of 
the tumor in both lateral ventricles and elimination of risks 
associated with cortical transgression. Although the risks of 
transcallosal approach include injury to the parasagittal veins 
and subsequent venous infarct,[23,36] we did not encounter any 
Figure 1: CN (a) limited to the frontal horn of the left lateral ventricle, (b) medial tumor, (c) posterior location, and (d) very large CN casting 
the lateral ventricles. CN: Central neurocytoma.
a b c d
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Table 3: Classification of CN based on the size and location.
Size Number of 
patients











31 (25%) Group B: medial (in 




III: large  
(4–6 cm)
58 (46%) Group C: posterior 






17 (14%) Group D: extensive 
(involving several parts 
of the lateral ventricles, 
or casting them)
17 (14%)
Total 125 Total 125
CN: Central neurocytoma
large bridging cortical veins in the surgical field in any of the 
40 patients operated on through this approach. In 25 patients 
with asymmetrical location of the tumor, we opened up the 
corpus callosum most often between pericallosal arteries or 
lateral to the ipsilateral pericallosal artery. e size of corpus 
callosotomy depends on the size of the tumor, but never 
larger than 2  cm in our series. Typically, the callosotomy 
was carried out in the anterior or middle part of the body 
of the corpus callosum, depending on the location of the 
major bulk of the tumor. If severe hydrocephalus is present, 
this approach allows the removal of tumors located more 
posteriorly, in the body of the lateral ventricle and if the 
lesion involved both lateral ventricles.
In four cases of giant tumors casting the lateral ventricles 
and extending into the third ventricle, we used combined 
approaches: three patients were operated on through 
transcortical and transcallosal approaches, and in one case, 
through bilateral transcortical approach.
Microsurgical nuances
We found that positioning of the patient on the operating 
table with maximum utilization of gravity, adequate 
brain relaxation and wide tumor exposure are critical to 
successful removal of CN. In 35  patients, the surgeons 
reported relatively soft consistency of the tumor, which 
allowed an efficient utilization of regular suction and 
ultrasonic aspirator. Multiple tumor vessels were 
coagulated within the parenchyma of the tumor. We tried 
to avoid or minimize the use of coagulation on the walls of 
the lateral ventricles to minimize the risk of normal brain 
damage. Securing the bleeding from the hypertrophied 
ependymal vessels was frequently challenging. e 
ependymal feeders commonly have very thin and frail 
walls and continue to bleed, even as they retract into the 
normal brain. Local hemostatic agents, such as gelfoam 
soaking wet in thrombin and oxidized cellulose were 
helpful. When the anterior-inferior aspect of the tumor 
is mobilized, it is important to visualize the foramina of 
Monro and carefully preserve the fornices. In 30 patients, 
the tumors were extending into the third ventricle. In 
these cases, we did not encounter any serious adhesions 
between the tumor and the walls of the third ventricle. 
e surgeons were able to mobilize and aspirate the 
tumor through the foramen of Monro without the need to 
widen the transforaminal exposure. alamostriate veins 
were preserved in all patients, including 12  cases, when 
the tumor was densely adherent to them, utilizing sharp 
dissection. In eight cases, a very thin layer of tumor was 
left on the thalamostriate veins to preserve them. Septal 
veins were either unidentifiable, or sacrificed in all cases, as 
neoplasms invaded septum pellucidum. When the tumor 
invaded choroid plexi, we tried to preserve their largest 
draining veins until the very end of resection. eir early 
sacrifice could contribute to significant intraoperative 
hemorrhage that resulted in challenging hemostasis during 
removal of the posterior pole of the tumor. We attempted 
maximally aggressive resection, as bleeding into the 
residual mass can result in potentially life-threatening 
sequela of postoperative intraventricular hemorrhage and 
even casting of the ventricular system with blood, resulting 
in obstructive hydrocephalus. To prevent obstructive 
hydrocephalus, microsurgical fenestration of the septum 
pellucidum was performed in almost all cases [Figure 2].
Ventriculostomy catheter was left in 85 (68%) of the patients. 
Seven most recent consecutive patients with large CN 
underwent prophylactic intraventricular stenting to prevent 
hydrocephalus between the anterior and posterior horns 
of the lateral ventricles or between the lateral and third 
ventricles. Early postoperative brain computed tomography 
(CT) (within 3  h of surgery) was performed in all cases to 
rule out acute postoperative changes, such as hemorrhage 
and hydrocephalus.
Neuromonitoring of somatosensory evoked potentials 
(SSEP) and motor evoked potentials (MEP) was utilized 
in 82  patients with posteriorly located, extensive tumors, 
and tumors infiltrating the walls of the lateral ventricles. In 
addition, continuous subcortical stimulation was performed 
during tumor resection. e authors did not monitor patients 
with smaller and anteriorly located neoplasms.
RESULTS
Extent of resection
In this series of 125  patients, GTR was documented in 
45 (36%), STR in 40 (32%), and PR in 40 (32%) of patients. 
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Table 4: Size of the tumor and extent of resection.
Group/Size 
of the tumor
GTR STR GTR+STR PR Total
Group I: 
small (<2 cm)




15 7 22 (69%) 9 (31%) 31
Group III: 
large (4–6 cm)
12 23 35 (66%) 23 (34%) 58
Group IV: 
giant (>6 cm)
2 7 9 (50%) 8 (50%) 17
Total 45 (36%) 40 (32%) 85 (68%) 40 (32%) 125
GTR: Gross total resection, STR: Subtotal resection, PR: Partial resection
Further analysis of the relationship of the preoperative 
tumor volume and the EOR demonstrated that GTR/STR 
was achieved in 100% of patients with tumors <2.0  cm 
in largest diameter, in 69% of the patients with tumors 
measuring 2–4 cm, in 66% with tumors measuring 4–6 cm, 
and in only 50% when lesions were larger than 6  cm 
[Table 4].
In patients with anterior tumors (Group  A), aggressive 
resection (GTR and STR) was achieved in 65% of cases (28 
out of 43 patients). In patients with medial tumors (Group B), 
aggressive resection (GTR and STR) was achieved in 74% (40 
out of 54) of patients. In Group C patients (posterior tumors), 
64% (7 from 11) had aggressive resection. In patients with 
extensive tumors (Group D) GTR/STR was possible in only 
56% of cases (9 out of 16 patients) [Table 5].
Even with neuromonitoring, 22 of 82  patients with large 
posterior infiltrating lesions developed either worsening of 
the weakness, or new motor deficits. Interestingly, only 15 
of 22  patients had documented decrease in the amplitudes 
of SSEP and MEP. Further resection of the periventricular 
and/or thalamic parts of the tumor was stopped in each case 




A total of 26 patients (21%) were found to have postoperative 
hemorrhage in the resection bed. In all cases, the bleeding 
was associated with residual tumor. Postoperative hematomas 
were more common in patients with large or giant tumors 
(n = 22). Radiographically, the volume of hemorrhage 
was comparable with, or larger than the volume of the 
original tumor in all cases. We found that 85% of the bleeds 
(n = 22) occurred within the first 24  h after surgery. Only 
three patients were stable enough to manage conservatively, 
whereas in 19 cases, surgical revision and evacuation of the 
intraventricular hematoma with resection of residual tumor 
were performed within 24–48 h postoperatively. In addition, 
four patients experienced second rebleeding on postoperative 
days 3–5 (after the first revision). ese patients were 
operated on again within 4–6 days after craniotomy for tumor 
removal. In the group of 19 patients who had to undergo an 
emergent evacuation of the hematoma due to significant 
mass effect, brain shift and/or herniation, two patients died 
and two were discharged in persistent vegetative state.
Further analysis of hemorrhagic complications and their 
relationship with the type of approach and location of the 
tumor showed that hematomas most commonly occurred 
after transcortical approach (16 of 76  patients/64%), 
followed by combined approach (2 of 4  patients/50%), 
and less commonly, after transcallosal approach (8 of 
40  patients/31%). Postoperative hematomas were most 
common in group  C (3 of 11  patients/27%), followed 
by Group  A (9 of 43  patients/21%); Group  D (3 of 
17 patients/18%); and Group B (8 of 54 patients/15%).
Subdural collections
ree patients developed acute postoperative subdural 
hematomas and one patient was diagnosed with subdural 
Figure  2: Basic principles of microsurgical resection: (a) in most 
cases, the tumor is relatively soft, which allows an efficient use of 
the regular suction and ultrasonic aspiration; (b) multiple tumor 
vessels are coagulated in the parenchyma of the tumor. e use of 
coagulation on the walls of the side ventricles should be avoided 
or minimized; (c) if the tumor is located in the lower part of the 
anterior horn, it is important to visualize and release the foramen 
of Monro by removing the tumor through it without the need to 
expand the transforaminal exposure while preserving the fornix. 
alamostriate vein and the vein of the choroid plexus should be 
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Table 5: Location of the tumor, surgical approach, and extent of resection.
Surgical approach Group A: anterior 
tumors (n=43)
Group B: medial 
(n=54)
Group C: posterior 
(n=11)
Group D: extensive 
(n=17)
Total
Tot (GTR/STR) PR Tot (GTR/STR) PR Tot (GTR/STR) PR Tot (GTR/STR) PR
Anterior transcallosal 8 (5/3) 4 20 (11/9) 8 - - - - 40
Anterior transcortical 20 (12/8) 11 20 (11/9) 6 6 (3/3) 3 6 (1/5) 4 76
Posterior transcortical - - - - 1 (1/0) 1 1(0/1) 2 5
Combined - - - - - - 3 (1/2) 1 4
Total 28 (17/11) 15 40 (22/18) 14 7 (4/3) 4 10 (2/8) 7 125
GTR: Gross total resection, STR: Subtotal resection, PR: Partial resection
hygroma 8  days after craniotomy. None of them required 
surgical evacuation.
Impaired CSF circulation and absorption
Hydrocephalus
Obstructive hydrocephalus was noted in 25  (20%) 
patients. In 80% of the cases progressive worsening of 
ventriculomegaly occurred acutely, on postoperative 
days 2 and 3. In 19  cases, the external drain was placed. 
Consequently, 14 of the 19  patients with external drain 
ended up with ventriculoperitoneal shunt. Shunting 
procedures for obstructive hydrocephaly were performed 
in a delayed fashion (10–35  days after the first surgery), 
once CSF had become visually clear. In 5 of 14 patients who 
underwent shunt placement, the procedure was performed 
on postoperative days 30–35 due to meningitis, which was 
treated with IV vancomycin until CSF analysis became 
normal and cultures negative. We did not observe any 
mortality or significant morbidity related to CSF infection.
Interestingly, although we did not establish any clear 
correlation between the extent of resection and development 
of hydrocephalus, over 50% of hydrocephalus cases occurred 
after STR and PR of the tumor. In 15 patients after GTR, the 
occlusion was at the level of the foramina of Monro due to 
direct obstruction by the blood clots. In 10  patients after 
PR, the obstruction was related to the presence of both, 
“strategically placed” residual tumor tissue in the vicinity 
of the foramina of Monro and blood clots. Hydrocephalus 
developed in 17  patients after transcortical approach, five 
patients after transcallosal approach, two patients after 
combined approach, and in one case after tumor resection 
through the superior parietal lobule.
Entrapment of the occipital and/or temporal horns
A unique complication was encountered in Group C patients 
(with posteriorly located tumors): the entrapment of the 
occipital and/or temporal horns. is problem occurred in a 
total of 7 of 11  patients in Group  C. Once the high risk of 
entrapment was realized, all seven subsequent patients were 
prophylactically stented to establish connection between the 
posterior-inferior aspects of the lateral ventricles and the rest 
of the ventricular system.
In three of seven patients, the intraventricular stents extended 
through the foramina of Monro and the aqueduct [Figure 3]. 
Intraventricular stenting was performed with utilization of 
the ventricular catheter, trimmed to achieve desired length. 
In all cases, surgeons added several side holes to minimize 
the chances of occlusion. e stents were not anchored. 
ere were no incidents of stent occlusion, malfunction, or 
migration. None of the patients after stenting required shunt 
placement or any other type of revision surgery.
Neurological outcome
All postoperative patients experienced early neurological 
and cognitive worsening to some extent. In half of the 
patients (n = 62, 50%), the symptoms were mild, included 
increased somnolence, decreased level of activity, 
sensorimotor agitation, and anxiety, and improved within 
the 1st  postoperative week. e other 63  patients had a 
more complicated course, characterized by significant 
disorientation, attention deficit, global amnesia, short-
term memory deficits, and perceptual motor and social 
cognition problems. In 22 (of 63  patients in this group), 
the neurocognitive problems remained permanently. All 
28 patients (22%), who presented with neurocognitive deficits 
before surgery, were found to have further neurocognitive 
decline [Table  6]. Postoperative GCS score distribution 
among the alive patients was 14–15 in 51 cases, 12–13 in 62, 
and 9–11 in seven patients.
Analysis of the postoperative complications and tumor 
location revealed the following relationships: patients with 
anteriorly located lesions (type  A and/or B) were more 
likely to have memory and cognitive disturbances, whereas 
patients with posteriorly located and extensive tumors (type 
С and/or D) were prone to have signs of pyramidal tract 
damage (i.e. hemipares) and speech disturbance. Among the 
11 patients with posteriorly located tumors (types C), partial 
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Table 6: Clinical presentation of 125 patients with CN before and 
after microsurgery.
Clinical manifestation Before surgery After surgery
Memory decline 40 (32%) 62 (50%)
Other psychiatric and cognitive 
disturbances
28 (22%) 32 (27%)
Signs of increased ICP 78 (62%) -
Upper motor neuron signs 
(hemiparesis and hyperreflexia)
15 (12%) 22 (18%)
Double vision due to abducens 
nerve palsy
2 (1.7%) 4 (3.6%)
Visual field loss 2 (1.7%) 4 (3.6%)
Speech disorders - 11 (9%)
Overall number of patients 125 120 alive 
patients
ICP: Intracranial pressure, CN: Central neurocytoma
Table 7: Comparison of the nature of postoperative complications 
























0 7 7 8
Double vision 
due to abducens 
nerve palsy
0 0 0 4
Visual field loss 0 0 2 2
Speech disorders 0 2 4 4
hemianopsia was diagnosed in two. After surgery, these 
patients and two others developed complete hemianopsia on 
formal visual field evaluation [Table 7].
Mortality
Five patients (4%) died in the early postoperative period. All 
deaths were related to hemorrhage into the residual tumor, 
with resultant mass effect and compression of the brainstem. 
Two patients underwent revision within 24  h of surgery. 
Although some improvement of the brainstem function was 
noted after decompression (i.e. hemodynamic stabilization), 
their neurological status remained extremely poor. In one 
patient, postoperative hemorrhage was complicated by sepsis 
and subsequent multisystem organ failure that ultimately 
lead to expiration.
Tumor recurrence
CN’s are slowly growing tumors. erefore, only patients 
with long-term follow up were selected for analysis of data 
on recurrence. After surgical treatment from 2008 to 2018, 
84  patients with CNs were followed for 2–10  years (mean 
6  years). Of those 84  patients, 26  (30.2%) were found to 
have tumor recurrence within 12–96  months after surgery; 
in 19  cases after incomplete resection, and in seven cases 
after GTR. Two-year progression-free survival (PFS) was 
documented in 94% and 5-year PFS in 73% of the patients 
[Figure 4].
e multivariate analysis of factors potentially affecting the 
recurrence rate revealed that the EOR and the range of Ki-67 
proliferative index were associated with the most significant 
impact [Figure 5 and Table 8]. Five-year PFS was 90% after 
GTR and only 65% after subtotal and partial resection 
(P < 0.05). In patients with Ki-67 index <5%, 83% experienced 
5-year PFS versus only 40% in patients with Ki-67 index ≥5% 
(P < 0.05). e Kaplan–Meier estimator curve illustrating the 
PFS in relation to Ki-67 index is provided in [Figure 6].
Management of recurrent tumors
Continuous observation
Of 26  patients with recurrent CN’s, eight cases were 
managed conservatively with serial imaging studies because 
the documented increase in size of the recurrence was 
≤2  mm in each case and Ki-67 index ≤5%. None of the 
patients in this subgroup showed any further increase in the 
tumor size.
Figure  3: (a) Preoperative MRI (T1 with contrast) showing the 
tumor involving both lateral ventricles; (b) postoperative brain 
CT after resection of recurrent neurocytoma and stenting of the 
left lateral ventricle: the longer stent extends from the occipital 
horn of the right lateral ventricle to the frontal horn on the left; the 
shorter stent connects the right frontal horn and the body of the 
lateral ventricle. MRI: Magnetic resonance imaging, CT: Computed 
tomography.
ba
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Table 8: e multivariate analysis of factors potentially affecting the recurrence rate: the EOR and the range of Ki-67 proliferative index 
were associated with the most significant impact.
Covariate b SE Wald P Exp (b) 95% CI of Exp (b)
Ki_67 2.3250 0.4337 28.7427 <0.0001 10.2265 4.3710–23.9262
Max_diameter 0.8698 0.4062 4.5850 0.0323 2.3864 1.0764–5.2909
EOR 1.2911 0.4115 9.8430 0.0017 3.6369 1.6234–8.1476
EOR: Extent of resection, SE: Standard error, CI: Confidence interval
Figure 4: Progression-free survival.
Figure 5: Survival function at mean of covariates.
Figure 6: Progression-free survival and Ki-67 values (P<0.05).
Repeat surgical resection
Seven patients were diagnosed with significant postoperative 
radiographic tumor progression associated with mass-
effect, hydrocephalus, and/or development of neurological 
deficits. ey subsequently underwent repeat craniotomy 
for resection of recurrence. In five of these cases, GTR 
was achieved, 82% of patients in this subgroup improved 
neurologically and cognitively or remained unchanged. 
None of the patients experienced surgical complications. 
e authors impression was that repeat surgeries were less 
technically challenging, as the lesions were smaller than in 
the first surgery and tended to be less vascular. In all cases, 
the lesions were well defined with clearer borders than in 
the original procedures. e images of one of the illustrative 
cases are depicted in [Figure 7].
Radiation therapy
Eleven patients were found to have significant interval 
enlargement of the tumor on follow-up MRI. ey did not 
have evidence of increased ICP/mass effect, or impaired 
CSF circulation/hydrocephalus. ese patients were felt to 
be good candidates for radiation therapy (XRT). e choice 
of XRT methods depended on the volume of residual tumor 
and the extent of tumor spread in the ventricular system. e 
XRT techniques are summarized in [Table 9].
All 11  patients with recurrent CN treated with XRT 
demonstrated satisfactory results over the mean follow-up 
of 2.5  years. e tumor decreased in size in 4  patients and 
remained stable in 7 [Figure 8].
None of the patients had evidence of radiation-induced 
damage to the surrounding tissues on follow-up MRI. Eight 
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Table 9: XRT techniques, dosage and fractionation used in patients with recurrent CN.








Fractionation XRT machine Number of patients




2.7–11.7 8.8 21.0–27.5 - 7 Gy × 3;




12.0–62.0 35.0 54 - 1.8 Gy × 30;
2 Gy × 27
Novalis® 3
TrueBeam® 2
XRT: Radiation therapy, CN: Central neurocytoma, SRS: Stereotactic radiosurgery
patients treated with XRT developed clinically significant 
problems with CSF circulation and/or absorption. In two 
cases of communicating hydrocephalus shunt placement 
was performed 6 and 12  months after XRT respectfully. 
e remaining six patients developed entrapment of the 
temporal and/or occipital horns of the lateral ventricles. is 
complication was observed when the tumor extended into 
the posterior body and/or trigonum of the lateral ventricles. 
e ventricular entrapment was discovered on neuroimaging 
studies between 6 and 18 months after XRT. ese patients 
were managed with either endoscopic or open microsurgical 
membrane fenestration or lysis of intraventricular adhesions 
with successful restoration of normal CSF circulation 
in all cases [Figure  9]. We did not observe any cases of 
pseudoprogression.
DISCUSSION
CN is biologically benign, slowly growing neoplasms with 
an overall favorable chance of survival. CN is most common 
in young adults, potentially most productive age group 
(between ages of 20 and 40 years).[20,36,54]
Our literature search identified close to 500 reported cases 
of CN. e largest clinical series to date was by Rades and 
Schild with 438 cases (365 adults and 73 pediatric patients). 
Interestingly, 87  patients in this series were found to have 
atypical CN.[43] Other large series included 92  patients by 
Qian et al., 84 and 115  patients by Konovalov et al., and 
63 cases by Wang et al.[24,25,41,51]
ese series are summarized in [Table 10].
Early reports including our recent publication described 
high rates of complications and low resection rates.[24] In the 
original series of Hassoun et al. and subsequent report by 
Nishio et al. only 50% of the patients had GTR.[19,38] In the 
Figure 7: (a) Preoperative MRI of the tumor with Ki-67 index >5% (T1 with contrast); (b) T1 MRI with contrast 6 months after surgery, with 
evidence of GTR of the tumor; (c) T1 MRI with contrast 3 years after surgery showing large recurrent tumor; (d) immediate postoperative T1 
MRI with contrast demonstrated GTR of the lesion. MRI: Magnetic resonance imaging, GTR: Gross total resection.
c da b
Figure 8: Illustrative case of the XRT plan in a patient after standard 
fractionated treatment to the recurrent tumor (a), total dose of 
57.6 Gy; T1 MRI 12 months after XRT demonstrated significant 
decrease in size of the tumor (b) XRT: radiation therapy, MRI: 
magnetic resonance imaging.
ba
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last decade, however, a higher number of patients underwent 
more radical resections, ranging from 71% to 91% with 
acceptable morbidity.[8,23,41]
is was probably due to earlier detection of tumors by 
neuroimaging, improvements in microsurgical techniques 
and introduction of routine image-guidance and 
intraoperative MRI.[2] Nowadays, maximal safe resection 
has become the standard first line of treatment in patients 
with CN. e main objectives of surgery are to provide 
tissue for diagnosis, decompress the brain and treat 
hydrocephalus.[34,47]
Challenges related to the tumor location and size
CN is characterized by their deep intraventricular location 
and ample blood supply from the choroidal arteries. Other 
factors include their large size at presentation and early 
involvement of such critical structures as thalami and 
fornices.[8,19,23,26,29,34,36,38,51] e current consensus is that 
aggressive resection is not recommended if the tumor 
infiltrates the fornices, thalami, or encases the large 
intraventricular veins.
Many authors noted strong correlation between the EOR and 
tumor recurrence.[1,39,42,50] However, due to the mechanism 
of the tumor growth with wide infiltration of the ventricular 
walls, GTR might be challenging in many cases, and safely 
possible only in smaller and better circumscribed lesions.
Our GTR rate is lower than in the largest published series 
up to date by Chen et al.[8] It is felt to be mainly due to 
larger size of the lesions at presentation in our report. In the 
present study, 69 of 125 patients (55%) presented with large 
or giant tumors. e mean tumor size was 5.2 cm, compared 
to 4.8 cm reported by Chen et al. We demonstrated a very 
strong relationship between the size and the extent of 
resection of the tumor. GTR/STR was achieved in 100% of 
patients with tumors <2.0  cm in largest diameter, in 69% 
of tumors measuring 2–4 cm, in 66% of tumors measuring 
4–6  cm, and in only 50% when lesions were larger than 
6  cm. In five cases, we utilized endoscopic assistance, 
primarily to visualize residual tumor in the ventricular 
system. Despite successful use of the 0° and 30° scopes and 
adequate magnification, in three cases the surgeons failed 
to differentiate tumor from normal tissue. Overall, our 
experience with endoscopic assistance was not felt to be 
clearly advantageous.
Table 10: e most representative series of patients with neurocytomas and the results of surgical treatment.
Author Year n Radical resection Hydrocephalus Shunt Postoperative neurologic 
symptomatology
Mortality
Qian et al., 2012 [41] 2012 92 65 (71%) 62% 14% 40% 3 (2.5%)
Konovalov et al., 2006[24] 2006 84 11+48 (13+58%)
(GTR+STR)
33 (40%) 14 (17%) 17 (21%) 10 (12%)
Wang et al., 2018[51] 2018 63 34 (54%) 25 (40%) - 14 (22%) 5 (8%)
Chen et al., 2016[8] 2016 32 29 (91%) 3 (9%) 1 (3%) 6 (19%) 0
Kim et al., 2013[23] 2013 58 42 (88%) 10 (17%) - 14 (24%) 1 (2%)
Hallock et al., 2011[17]  2011 19 10 (53%) - - 16% 5%
Present series 2020 125 45+40 (68%)
(GTR+STR)
25 (20%) 14 (11%) 22 (18%) 5 (4%)
GTR: Gross total resection, STR: Subtotal resection
Figure  9: (a) CN involving both lateral ventricles before and 
(b) after surgery; (c) entrapment of the occipital horn of the left 
lateral ventricle (6 months after surgery); (d) follow-up MRI 6 
months after open microsurgical lysis of intraventricular adhesions, 
showing successful interval decompression of the trapped ventricle. 
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Although aggressive resection should be an ideal goal, 
Leenstra et al. reported no difference in overall outcome in 
patients after GTR and STR.[26] Other authors recommend 
a more conservative resection combined with stereotactic 
radiosurgery (SRS) as a method of choice to minimize the 
treatment related risks. e combined approach provides 
excellent long-term control of this biologically low-grade 
neoplasm.[20]
Choice of the approach
e choice of the surgical approach depends on three 
factors: (1) location of the tumor, (2) size, and (3) extent of 
hydrocephalus.[20,31,41] Transcortical approach through the 
premotor cortex was used in the majority of our patients. 
is approach is advantageous in cases associated with 
significant ventriculomegaly and asymmetrically located 
tumors occupying large portions of the lateral ventricles. 
Transcallosal approach is preferable in centrally located 
tumors in the anterior parts of the lateral ventricles. In rare 
cases of giant CN, a combined approach might be necessary. 
Various combinations of transcallosal and transcortical and 
bilateral transcortical approaches can be utilized. orough 
analysis of preoperative imaging studies can be very helpful 
in selecting the best approach. Kim et al. found no difference 
in the extent of resection and the actuarial overall survival 
between the surgical approaches.[23] However, there was a 
difference in functional outcomes, especially in the risk of 
cognitive deficits and seizures, that were more common after 
transcortical resection. erefore, if feasible, interhemispheric 
transcallosal route should be the approach of choice, as it 
provides the least disruptive anatomical corridor associated 
with smaller risk of approach related complications.[8]
e ipsilateral interhemispheric posterior parieto-occipital 
approach and the posterior interhemispheric transfalcine 
transprecuneus approach can be utilized to resect tumors 
located in the trigonum and the occipital horn of the lateral 
ventricle. ese approaches provide a wider surgical corridor, 
which leads to minimal retraction, sparing of the optic 
radiation, temporal, and parietal cortices and early access to the 
arterial feeders. e disadvantages include significant ipsilateral 
hemispheric retraction; long working distance; and risk of 
injury to contralateral hemisphere.[5,11,30] To prevent damage to 
the critical visual fibers in patients with very posteriorly located 
CN, the ipsilateral interhemispheric posterior parieto-occipital 
and the posterior interhemispheric transfalcine transprecuneus 
approaches can be considered a reasonable alternative to the 
trans-superior parietal lobule approach.[40]
Prevention and management of complications
Most CN series report high incidence of complications, 
including hemorrhage, obstructive hydrocephalus, 
neurological deficits, seizures, and cognitive deficits.[8,19,22-
24,38,45,51] Lubrano et al. reported 66% complication rates in 
their multicenter study. e main causes of postoperative 
disability were motor deficits and/or aphasia, memory 
problems (29%), and hydrocephalus (26%).[29] Higher 
complication rates in early publications might be related 
to larger size of the tumor, likely due to delayed patient 
diagnosis in the previous decade.[15,19,36,38,45] In our series, most 
significant complications were associated with hemorrhage 
and/or hydrocephalus. Postoperative hemorrhage is probably 
the most life-threatening complication. We agree with the 
observation of Chen et al. that difficult hemostasis and 
frequent hemorrhagic complications in CN can be explained 
on the basis of abundant blood supply with presence 
of multiple pathologic vessels without smooth muscle 
cells and well-developed network of cavernous venous 
structures.[8] Hematomas typically form in the residual 
tumor and frequently require revision of craniotomy and 
evacuation. Eighteen of the 26 patients with life-threatening 
hematomas in our report were operated on emergently. e 
morbidity and mortality in this group of patients were very 
high: two of them died and two were discharged in persistent 
vegetative state. We also noted that none of the patients 
operated on in a delayed fashion, that is, 4–6 days after the 
hemorrhage, or after the first emergent revision, died. In 
fact, all of them improved after hematoma evacuation. ese 
findings support our previous observation that delayed 
evacuation of hematoma (i.e.  after stabilization of the clot) 
may be beneficial in selected stable patients and can lead to 
somewhat easier hemostasis.[24] Analysis of the hemorrhagic 
complications revealed that postoperative hematomas occur 
twice as frequent after transcortical approach, compared to 
transcallosal. is finding might be related to the fact that 
transcortical approach is typically selected for larger tumors 
that also tend to be more infiltrative with more robust blood 
supply from the surrounding periventricular white matter. 
We did not find any correlation between the occurrence of 
hematoma in the resection bed and location of the tumor. 
Chaves et al. reported resection of a giant pediatric CN after 
successful preoperative embolization, which supposedly 
resulted in smaller blood loss.[7] e patients in our series did 
not receive preoperative embolization.
Obstructive hydrocephalus is another dangerous 
complication, especially if develops acutely in the early 
postoperative period. Soliman suggested that tumor 
remnants and blood clots are the main causes of obstruction 
of the CSF pathways.[47] We concur with this observation. 
e incidence of early postoperative hydrocephalus in 
the current study (20%) is almost half the incidence in 
the historic series and comparable to the results reported in 
the modern studies.[8,19,38,51] Seven patients in this series were 
found to have entrapment of the occipital and/or temporal 
horns. All these patients belonged to Group  C, harboring 
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posteriorly located tumors. Prophylactic intraventricular 
stenting appears to be beneficial in eliminating the risk 
of entrapment and subsequent shunting. e authors 
consider stenting a more physiological and less invasive 
procedure, as the CSF flows across the stent in both 
directions, as opposed to unidirectional flow toward the 
shunt, and then outside of the cranium. is is probably a 
pathophysiological basis for essential absence of cases of 
stent occlusion in this series. However, if CSF resorbtion is 
impaired, stenting alone may be insufficient. e authors 
acknowledge the small number of patients who underwent 
stenting and recommend a judicious use of this technique 
in selected cases of large posteriorly located tumors with 
intraventricular obstruction.
Postoperative hydrocephalus was twice as common after 
transcortical resection (22.3%) as after transcallosal resection 
(12.5%). e difference is likely also related to the larger 
volume and extent of ventricular involvement in patients 
undergoing transcortical resection. In addition, transcallosal 
approach allows better visualization and decompression of 
both foramina of Monro and the third ventricle.
Long-term management
Between 2008 and 2016, the authors utilized the 2008 World 
Health Organization (WHO) classification. After 2016, the 
new WHO classification has been used.[27,28] Ki-67 index 
was established in all patients to determine proliferative 
activity. Ki-67 index has become a very useful parameter 
in prognostication and evaluation of tumor response to 
treatment.[10,25,48] In our series of 25  patients with disease 
progression, 14 (56%) had Ki-67 index ≥5%. is factor was 
found to be statistically significant on multivariate analysis 
(P < 0.05). Conversely, low Ki-67 index (<5%) combined 
with aggressive tumor resection was found to be associated 
with longer PFS.
Patients with recurrent CN could be considered candidates 
for repeat microsurgical resection or XRT. Seven of 
16 patients in this series, with radiographic and symptomatic 
progression underwent repeat microsurgical resection. Most 
of them (86%) had a GTR of the tumor with good results, 
which proves that repeat surgical resection remains safe and 
effective long-term management strategy.
XRT was reserved for the patients with radiographic 
progression without evidence of increased ICP and/or 
hydrocephalus. e high efficacy of various forms of XRT was 
demonstrated in several publications with adequate long-term 
tumor control rate exceeding 80%.[9,48] e largest series of CN 
treated with XRT up to date, is a report of 42 consecutive cases 
treated with SRS, by Karlsson et al. in 2012.[21] e majority 
of their patients underwent SRS to the tumor remnants after 
STR. About 91% and 81% tumor control rates were achieved 
at 5 and 10  years, respectively.[3,4,12,14] e results of SRS in 
patients with CN’s are summarized in [Table 11].
Our data and review of the literature demonstrate that 
the use of various XRT modalities in recurrent CN cases 
is safe and associated with high tumor control rates. Rare 
cases of hemorrhage, edema, and radiation necrosis are 
typically self-limited and not associated with major negative 
clinical sequela. In patients with obstructive hydrocephalus, 
who would otherwise be considered good candidates 
for XRT, surgical CSF diversion (using microsurgical 
approaches, shunting, and/or stenting) should be performed 
before irradiation. Although we did not observe tumor 
pseudoprogression in our series, this condition was described 
in the literature. Pseudoprogression is associated with benign 
course and managed conservatively.
Table 11: e results of SRS in patients with CN’s in the literature.





Yamanaka et al., 2016 [52] 36 Gamma Knife® 4.9 15.0 54.5 94 Hemorrhage-2; 
Radiation necrosis-1
Monaco et al., 2015[34] 8 Gamma Knife® 5.5 14.6 63.3 100 None
Kim et al., 2013[22] 20 Gamma Knife® 11.0 15.4 103 85 Edema-1
Karlsson et al.,2012[21] 42 Gamma Knife® 12.0 13.0 73 95 None
Genc et al., 2011[14] 22 Gamma Knife® 13.4 16.4 36 95 Hemorrhagе-1
Yen et al., 2007[53] 7 Gamma Knife® 6.0 16.0 60 100 Alopecia-1, 
Edema-1, Radiation 
necrosis-1
Martin et al., 2003[32] 4 Novalis® 3.2 16.5 33 100 None
Anderson et al., 2001[3] 4 Gamma Knife® 7.0 17.0 17 100 None
Bertalanffy et al., 2001[4] 3 Gamma Knife® 3.9 12.8 60 100 None
Cobery et al., 2001[12] 4 Gamma Knife® 14.8 10.5 44 100 None
SRS: Stereotactic radiosurgery, CN: Central neurocytoma
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Rarely, CN can spread along the CSF pathways. Goyal et al. 
described a case of periventricular atypical neurocytoma 
after STR. e patient in this report underwent adjuvant 
focal radiotherapy and subsequently developed local and 
spinal leptomeningeal recurrence treated with salvage 
chemotherapy. e disease continued to progress, and the 
patient was offered comfort measures.[16] Fortunately, we did 
not observe this phenomenon in our series.
A literature review of 19 atypical cases with malignant 
behavior showed MIB-1 LI above 2% in 12 of 14 cases, and 
above 10% in those progressing within a year.[35] Seventeen 
patients had craniospinal dissemination. However, 
craniospinal irradiation was given to only three patients after 
documented craniospinal dissemination.[6,37,49] Rades and 
Schild, after an extensive review of 438  patients, including 
87 atypical CNs, with a minimum follow-up of 1 year, gave 
treatment recommendations for various CN subgroups. No 
adjuvant therapy is required after GTR. After STR, adjuvant 
radiation improves survival in atypical lesions in adults 
but not in children, while local control improves across all 
subgroups. Adults need doses exceeding 54 Gy while doses 
above or below 50 Gy have comparable outcomes in children. 
Authors recommended adjuvant RT doses of 50  Gy in 
children, 50–54 Gy in typical CN, and 56–60 Gy in atypical 
CN.[43]
In addition to leptomeningeal dissemination, other unusual 
cases of CN spreading all the way down into the fourth 
ventricle[44] and association of CN with other neoplasms, 
such as pituitary adenoma[46] have been described, none of 
which occurred in our patients.
Limitations of the study and future directions
Our study has several limitations: (1) the retrospective 
nature of the study introduces the possibility of selection 
bias and biased post hoc data analysis, especially when most 
surgeries were performed in one institution by the senior 
neurosurgeon; (2) since utilization of the intraoperative 
MRI was suggested to be associated with higher extent of 
resection, it could be advantageous to use this technique to 
better evaluate its impact (if any) on the surgical outcomes.
Most of these limitations could be successfully addressed 
in future prospective cohort studies. However, given the 
infrequency of this diagnosis, conduction of the large 
prospective studies of CN may encounter significant 
logistical and temporal difficulties. erefore, creation of 
prospective multi-institutional databases could become 
a more practical approach. Continuous refinement of 
microsurgical techniques, utilization of new technology, such 
as intraoperative MRI and judicious use of multimodality 
treatment may lead to further improvement in the outcomes, 
reduce morbidity and mortality.[8,17,23,41,51]
CONCLUSION
CN remains surgically challenging lesion. e results of this 
series are comparable to the results reported in previous 
studies. Although high rates of GTR or STR can be expected, 
the mortality and morbidity remain significant even in the 
modern neurosurgical era, regardless of the approach. Large 
size of the tumor, presence of hydrocephalus and preoperative 
neurological or cognitive deficits are associated with lesser 
extent of resection and poorer outcome. Prophylactic 
intraventricular stenting in patients with large posteriorly 
located tumors with hydrocephalus may prevent ventricular 
entrapment and shunting. Early diagnosis and continuous 
refinement of microsurgical techniques along with judicious 
use of multimodality treatment may positively impact the 
outcomes.
Despite an overall favorable prognosis, up to a third of the 
patients experience disease progression and recurrence. e 
main risk factors for recurrence are presence of residual 
disease and Ki-67 index over 5%. Recurrent symptomatic 
tumors should be treated surgically, whereas asymptomatic 
progression can be managed with SRS. Both treatment 
modalities are associated with low risk of complications and 
high tumor control rates.
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